Cargando…

P1443: AUTOLOGOUS NK CELLS AS CONSOLIDATION AFTER FRONT-LINE STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: A LONG-TERM FOLLOW-UP

Detalles Bibliográficos
Autores principales:	Lund, J., Nahi, H., Meinke, S., Holmqvist, P.-H., Ljunggren, H.-G., Aschan, J., Alici, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431254/ http://dx.doi.org/10.1097/01.HS9.0000848628.24223.c8

Ejemplares similares

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
por: Nahi, Hareth, et al.
Publicado: (2022)

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
por: Nahi, Hareth, et al.
Publicado: (2019)

COLLABORATION AGREEMENT K1443
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2007)

The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
por: Uttervall, Katarina, et al.
Publicado: (2014)

Outcome of COVID‐19 in multiple myeloma patients in relation to treatment
por: Susek, Katharina Helene, et al.
Publicado: (2020)

Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
por: Susek, Katharina H., et al.
Publicado: (2022)

Correction to Lancet Oncol 2020; 21: 1443–54
Publicado: (2020)

Front-line treatment of multiple myeloma
por: Cavo, Michele, et al.
Publicado: (2019)

NK Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation: Association Between NK Cell Maturation Stage and Outcome in Multiple Myeloma
por: Orrantia, Ane, et al.
Publicado: (2021)

Autologous cellular therapy for myeloma: Giving ex vivo expanded NK cells their due
por: Shapiro, Roman M., et al.
Publicado: (2022)

Autologous peripheral blood stem cell transplantation as front-line therapy for myeloma with double-hit and triple-hit in a real-world study
por: Yang, Guang-Zhong, et al.
Publicado: (2021)

1443. N-Acetyl Cysteine Coadministration in Prevention of Amphotericin--Induced Electrolytes Imbalances in Children
por: Arikan, Kamile, et al.
Publicado: (2019)

Trauma and Injuries Pattern During Hajj, 1443 (2022): A Cross-Sectional Study
por: Al-Hayani, Majed M, et al.
Publicado: (2023)

NK cell-based autologous immune enhancement therapy (AIET) for cancer
por: Terunuma, H, et al.
Publicado: (2013)

Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells
por: Chrobok, Michael, et al.
Publicado: (2019)

P1443: INTRAVENOUS FLUID REPLACEMENT THERAPY AND HOSPITAL OUTCOMES FOR VASO-OCCLUSIVE EPISODES IN PATIENTS WITH SICKLE CELL DISEASE
por: Haimed, Abraham, et al.
Publicado: (2023)

Multiple Myeloma Patients at Various Cytogenetic Risks Benefit Differently from Autologous Stem Cell Transplantation as a Consolidation Therapy
por: Zeng, Tianmei, et al.
Publicado: (2015)

1443. Characteristics of nursing homes with higher rates of invasive methicillin-resistant Staphylococcus aureus infections
por: See, Isaac, et al.
Publicado: (2023)

Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
por: Gran, Charlotte, et al.
Publicado: (2020)

Front line treatment of elderly multiple myeloma in the era of novel agents
por: Venon, Marie-Dominique, et al.
Publicado: (2009)

1443. Serotypes 8 and 3 Are the Leading Cause of Invasive Pneumococcal Disease in Adults in Portugal (2015–2017)
por: Silva-Costa, Catarina, et al.
Publicado: (2018)

1443. Nontuberculous Mycobacterial Cervicofacial Lymphadenitis Therapy: Experience from a Tertiary Care Pediatric Center
por: Vo, Anh N, et al.
Publicado: (2022)

P1435: PRECLINICAL EVALUATION OF ZILOVERTAMAB-BASED ANTI-ROR1 CHIMERIC ANTIGEN RECEPTORS IN NK AND T CELLS
por: Meinke, S., et al.
Publicado: (2022)

Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
por: García-Sancho, Alejandro Martín, et al.
Publicado: (2022)

Conditioning with melphalan 200 mg/m(2) and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care
por: Afram, Gabriel, et al.
Publicado: (2022)

The application of autologous cancer immunotherapies in the age of memory-NK cells
por: Lizana-Vasquez, Gaby D., et al.
Publicado: (2023)

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
por: Duru, Adil Doganay, et al.
Publicado: (2015)

NK Cell Subgroups, Phenotype, and Functions After Autologous Stem Cell Transplantation
por: Jacobs, Benedikt, et al.
Publicado: (2015)

Human NK Cells in Autologous Hematopoietic Stem Cell Transplantation for Cancer Treatment
por: Orrantia, Ane, et al.
Publicado: (2021)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

1443. Activity of Ceftazidime-Avibactam against Carbapemenase-negative Carbapenem-resistant Enterobacterales (CRE) Isolates from US Hospitals
por: Castanheira, Mariana, et al.
Publicado: (2020)

Hodgkin’s lymphoma: post- autologous transplantation consolidation therapy
por: Merli, Francesco, et al.
Publicado: (2020)

Comment on Manna et al. SARS-CoV-2 Inactivation in Aerosol by Means of Radiated Microwaves. Viruses 2023, 15, 1443
por: Taylor, Gavin J., et al.
Publicado: (2023)

The role of NK cells in HIV-1 protection: autologous, allogeneic or both?
por: Hens, Jef, et al.
Publicado: (2016)

Real‐world multiple myeloma front‐line treatment and outcomes by transplant in the United States
por: Richter, Joshua, et al.
Publicado: (2023)

Consolidation in multiple myeloma – current status and perspectives
por: Olszewska-Szopa, Magdalena, et al.
Publicado: (2014)

Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
por: Minnie, Simone A., et al.
Publicado: (2021)

Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma
por: Pazina, Tatiana, et al.
Publicado: (2021)

Hypoxia Induced Impairment of NK Cell Cytotoxicity against Multiple Myeloma Can Be Overcome by IL-2 Activation of the NK Cells
por: Sarkar, Subhashis, et al.
Publicado: (2013)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
por: Bird, Sarah A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gg4abgo1uj3hm92u4ma65bd3jt